Literature DB >> 23485612

Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations.

Dow P Hurst1, Marianne Schmeisser, Patricia H Reggio.   

Abstract

Class A G-protein coupled receptors (GPCRs) are thought to have a common topology that includes seven transmembrane alpha helices (TMHs) that are arranged to form a closed bundle. This bundle forms the ligand binding pocket into which ligands are commonly thought to enter via the extracellular milieu. This ligand approach direction makes sense for GPCRs that have small positively charged ligands, such as the beta-2-adrenergic or the dopamine D2 receptor. However, there is a growing sub-group of Class A GPCRs that bind lipid-derived endogenous ligands, such as the cannabinoid CB1 and CB2 receptors (with endogenous ligands, N-arachidonoylethanolamine (anandamide) and sn-2-arachidonylglycerol (2-AG)) and the S1P1-5 receptors (with endogenous ligand, sphingosine-1-phosphate). Even the widely studied Class A GPCR, rhodopsin, binds a highly lipophillic chromophore (11-cis-retinal). For these receptors, ligand approach from the extracellular milieu has seemed unlikely given that the ligands of these receptors readily partition into lipid or are actually synthesized in the lipid bilayer. The recent X-ray-crystal structure of the sub-type 1 sphingosine-1-phosphate receptor (S1P1) provides important information on the key structural variations that may be the hallmarks for a Class A GPCR that binds lipid-derived ligands. These include an extracellular domain that is closed off to the extracellular milieu and the existence of an opening between transmembrane helices that may serve as a portal for ligand entry via the lipid bilayer. This review examines structural aspects that the cannabinoid receptors may share with the S1P1 receptor based upon sequence homology. This review also examines experimental and simulation results that suggest ligand entry via a lipid portal is quite likely for this emerging sub-group.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485612      PMCID: PMC4034697          DOI: 10.1016/j.chemphyslip.2013.01.009

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  113 in total

1.  (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor.

Authors:  Robert P Picone; Atmaram D Khanolkar; Wei Xu; Lionel A Ayotte; Ganesh A Thakur; Dow P Hurst; Mary E Abood; Patricia H Reggio; Donna J Fournier; Alexandros Makriyannis
Journal:  Mol Pharmacol       Date:  2005-09-12       Impact factor: 4.436

2.  Identification and functional characterization of brainstem cannabinoid CB2 receptors.

Authors:  Marja D Van Sickle; Marnie Duncan; Philip J Kingsley; Abdeslam Mouihate; Paolo Urbani; Ken Mackie; Nephi Stella; Alexandros Makriyannis; Daniele Piomelli; Joseph S Davison; Lawrence J Marnett; Vincenzo Di Marzo; Quentin J Pittman; Kamala D Patel; Keith A Sharkey
Journal:  Science       Date:  2005-10-14       Impact factor: 47.728

3.  Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

Authors:  M Germana Sanna; Sheng-Kai Wang; Pedro J Gonzalez-Cabrera; Anthony Don; David Marsolais; Melanie P Matheu; Sindy H Wei; Ian Parker; Euijung Jo; Wei-Chieh Cheng; Michael D Cahalan; Chi-Huey Wong; Hugh Rosen
Journal:  Nat Chem Biol       Date:  2006-07-09       Impact factor: 15.040

Review 4.  Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches.

Authors:  P H Reggio
Journal:  Handb Exp Pharmacol       Date:  2005

5.  Peripheral cannabinoid receptor, CB2, regulates bone mass.

Authors:  Orr Ofek; Meliha Karsak; Nathalie Leclerc; Meirav Fogel; Baruch Frenkel; Karen Wright; Joseph Tam; Malka Attar-Namdar; Vardit Kram; Esther Shohami; Raphael Mechoulam; Andreas Zimmer; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-09       Impact factor: 11.205

6.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes.

Authors:  Régis Roche; Laurence Hoareau; Sandrine Bes-Houtmann; Marie-Paule Gonthier; Christine Laborde; Jean-François Baron; Yacine Haffaf; Maya Cesari; Franck Festy
Journal:  Histochem Cell Biol       Date:  2006-01-04       Impact factor: 4.304

7.  Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing.

Authors:  Karen Wright; Nicholas Rooney; Mark Feeney; Jeremy Tate; Duncan Robertson; Melanie Welham; Stephen Ward
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 8.  Lysophospholipids in the nervous system.

Authors:  Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2005-09       Impact factor: 3.072

Review 9.  Cannabinoid receptor signaling.

Authors:  A C Howlett
Journal:  Handb Exp Pharmacol       Date:  2005

10.  Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors.

Authors:  Aymen I Idris; Robert J van 't Hof; Iain R Greig; Susan A Ridge; David Baker; Ruth A Ross; Stuart H Ralston
Journal:  Nat Med       Date:  2005-05-22       Impact factor: 53.440

View more
  14 in total

Review 1.  Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.

Authors:  Robert P Picone; Debra A Kendall
Journal:  Mol Endocrinol       Date:  2015-04-13

2.  Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.

Authors:  David R Janero; Suma Yaddanapudi; Nikolai Zvonok; Kumar V Subramanian; Vidyanand G Shukla; Edward Stahl; Lei Zhou; Dow Hurst; James Wager-Miller; Laura M Bohn; Patricia H Reggio; Ken Mackie; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2015-05-29       Impact factor: 4.418

3.  Molecular Dynamics Methodologies for Probing Cannabinoid Ligand/Receptor Interaction.

Authors:  Diane L Lynch; Dow P Hurst; Derek M Shore; Mike C Pitman; Patricia H Reggio
Journal:  Methods Enzymol       Date:  2017-07-04       Impact factor: 1.600

Review 4.  New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery.

Authors:  Julia Park; Christopher J Langmead; Darren M Riddy
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-20

Review 5.  Molecular Targets of the Phytocannabinoids: A Complex Picture.

Authors:  Paula Morales; Dow P Hurst; Patricia H Reggio
Journal:  Prog Chem Org Nat Prod       Date:  2017

Review 6.  Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.

Authors:  David R Janero; Ganesh A Thakur
Journal:  Expert Opin Drug Discov       Date:  2016-10-21       Impact factor: 6.098

7.  Beyond radio-displacement techniques for identification of CB1 ligands: the first application of a fluorescence-quenching assay.

Authors:  Agostino Bruno; Francesca Lembo; Ettore Novellino; Mariano Stornaiuolo; Luciana Marinelli
Journal:  Sci Rep       Date:  2014-01-20       Impact factor: 4.379

8.  Polarized cellular patterns of endocannabinoid production and detection shape cannabinoid signaling in neurons.

Authors:  Delphine Ladarre; Alexandre B Roland; Stefan Biedzinski; Ana Ricobaraza; Zsolt Lenkei
Journal:  Front Cell Neurosci       Date:  2015-01-06       Impact factor: 5.505

Review 9.  Cannabinoids and Cannabinoid Receptors: The Story so Far.

Authors:  Fred Shahbazi; Victoria Grandi; Abhinandan Banerjee; John F Trant
Journal:  iScience       Date:  2020-06-20

Review 10.  CB1 Receptor Signaling in the Brain: Extracting Specificity from Ubiquity.

Authors:  Arnau Busquets-Garcia; Jaideep Bains; Giovanni Marsicano
Journal:  Neuropsychopharmacology       Date:  2017-09-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.